MRI versus CT and PET/CT in the Preoperative Assessment of Hodgkin and Non-Hodgkin Lymphomas

IF 0.9 Q4 HEMATOLOGY
Hemato Pub Date : 2021-10-01 DOI:10.3390/hemato2040041
F. Maccioni, Alessandro Calabrese, L. Manganaro, C. de Felice, Sara Cardaccio, M. López, Arianna Cleri, G. Capriotti, L. Petrucci, C. Catalano, A. Pulsoni
{"title":"MRI versus CT and PET/CT in the Preoperative Assessment of Hodgkin and Non-Hodgkin Lymphomas","authors":"F. Maccioni, Alessandro Calabrese, L. Manganaro, C. de Felice, Sara Cardaccio, M. López, Arianna Cleri, G. Capriotti, L. Petrucci, C. Catalano, A. Pulsoni","doi":"10.3390/hemato2040041","DOIUrl":null,"url":null,"abstract":"(1) Background: The purpose of this study is to retrospectively compare CT, MRI, and PET/CT in detecting lymphadenopathies and extra-nodal lesions in lymphoma and in disease staging. (2) Methods: Inclusion criteria were the availability of TB (Total Body) CT and/or PET/CT performed before treatment; MRI performed no later than 2 weeks after TBCT; histological confirmation of lymphoma; clinical-diagnostic follow-up. Using these criteria, we included 64/353 patients with TBCT and MRI performed at our hospital; 20/64 had PET/CT performed in other hospitals. Histology and follow-up were gold standard. (3) Results: The sensitivity, specificity, and accuracy in lymph nodes detection was 84.5%, 94.4%, and 91% for CT and 95%, 98.9%, and 95.6% for MRI. High agreement was observed between CT and MRI regarding the number and size of positive lymph nodes and for disease staging. MRI identified eight more extra-nodal lesions than CT. In the subgroup of 20 patients, PET/CT did not show a significant superiority in sensitivity, specificity, accuracy, and staging ability than CT and MRI. (4) Conclusions: Our study demonstrates a mild superiority of MRI over CT in lymphoma staging. Although PET/CT remains the reference standard, MRI demonstrated a similar diagnostic accuracy, with the added value of being radiation-free.","PeriodicalId":93705,"journal":{"name":"Hemato","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hemato","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hemato2040041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

(1) Background: The purpose of this study is to retrospectively compare CT, MRI, and PET/CT in detecting lymphadenopathies and extra-nodal lesions in lymphoma and in disease staging. (2) Methods: Inclusion criteria were the availability of TB (Total Body) CT and/or PET/CT performed before treatment; MRI performed no later than 2 weeks after TBCT; histological confirmation of lymphoma; clinical-diagnostic follow-up. Using these criteria, we included 64/353 patients with TBCT and MRI performed at our hospital; 20/64 had PET/CT performed in other hospitals. Histology and follow-up were gold standard. (3) Results: The sensitivity, specificity, and accuracy in lymph nodes detection was 84.5%, 94.4%, and 91% for CT and 95%, 98.9%, and 95.6% for MRI. High agreement was observed between CT and MRI regarding the number and size of positive lymph nodes and for disease staging. MRI identified eight more extra-nodal lesions than CT. In the subgroup of 20 patients, PET/CT did not show a significant superiority in sensitivity, specificity, accuracy, and staging ability than CT and MRI. (4) Conclusions: Our study demonstrates a mild superiority of MRI over CT in lymphoma staging. Although PET/CT remains the reference standard, MRI demonstrated a similar diagnostic accuracy, with the added value of being radiation-free.
MRI与CT和PET/CT在霍奇金淋巴瘤和非霍奇金淋巴瘤术前评估中的比较
(1)背景:本研究的目的是回顾性比较CT、MRI和PET/CT对淋巴瘤淋巴结病变和结外病变的检测及疾病分期。(2)方法:纳入标准为治疗前进行TB(全身)CT和/或PET/CT检查;MRI不迟于TBCT后2周;淋巴瘤的组织学证实;临床诊断跟踪。根据这些标准,我们纳入了在我院行TBCT和MRI检查的64/353例患者;20/64在其他医院做过PET/CT。组织学和随访均为金标准。(3)结果:CT对淋巴结检测的敏感性、特异性和准确性分别为84.5%、94.4%、91%,MRI对淋巴结检测的敏感性、特异性和准确性分别为95%、98.9%、95.6%。CT和MRI在阳性淋巴结的数量和大小以及疾病分期方面高度一致。MRI比CT多发现8个淋巴结外病变。在20例亚组患者中,PET/CT在敏感性、特异性、准确性和分期能力方面均未表现出明显优于CT和MRI。(4)结论:我们的研究表明MRI在淋巴瘤分期方面比CT有轻微的优势。虽然PET/CT仍然是参考标准,但MRI显示出类似的诊断准确性,并且具有无辐射的附加价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信